To assess the impact of differential BCL2 expression on the apoptotic machinery, we performed BH3 profiling25 and observed that MYC-amplified SCLC cell lines (n = 4) were more primed for apoptosis induction (Fig. 3a) especially by MS1 peptide, which acts as an MCL1 antagonist (MYC-amplified vs. non-MYC-amplified p = 0.01, two-tailed unpaired t test) (Fig. 3b). Here, MYC is linked to small cell lung carcinoma.